Aficamten Gets Breakthrough Tx Status for Obstructive Hypertrophic Cardiomyopathy
The designation was based on data from the phase 2 REDWOOD-HCM trial.
CHF And Arrhtyhmias
Decision on Furoscix Delayed Due to Inspection Requirements
Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, preprogrammed on-body drug delivery system.
Aclidinium Bromide May Increase MACE Risk in Those With CV Risk Factors
Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.
Genetic Risk, Lifestyle Predict CVD, Diabetes Independently
A total of 339,003 unrelated individuals of white British descent with available genotype and matching genetic data from the UK Biobank cohort study were included in the study.
Social Isolation, Loneliness May Increase AMI, Stroke Risk
The researchers found that 5,731 individuals had a first AMI and 3,471 had a first stroke over 7.1 years. Social isolation was associated with higher risk of AMI and stroke.
USPSTF: Assessing CVD Risk With Nontraditional Risk Factors
The researchers found that ABI is an accurate test for detecting PAD in symptomatic patients, but few data were available on the accuracy of ABI for identifying asymptomatic individuals who could benefit from treatment.
Empagliflozin Cuts CVD Risk in Patients With Type 2 Diabetes, PAD
At study start, 21% of the more than 7,000 EMPA-REG OUTCOME trial participants had existing peripheral artery disease.
Does Noninvasive Testing Improve Outcomes in Patients With Acute Chest Pain?
Noninvasive testing with CCTA or stress testing also leads to more radiation exposure, greater cost
Prexxartan Oral Solution Gets Tentative FDA Approval
The FDA’s final approval is pending the period of patent and/or exclusivity protection, and may not be made effective until the period has expired.
Updated Guidelines for Managing Ventricular Arrhythmias Released
“The risks of ventricular arrhythmias and sudden cardiac death vary in specific populations with different underlying cardiac conditions and with specific family history and genetic variants, and this variation has important implications for studying and applying therapies,” a guideline co-author said in a statement.
